MarketCap
Facebook
X
TelegramQuarterly report 2024-Q3
added 11-07-2024
Accelerate Diagnostics Operating Income 2011-2026 | AXDX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Accelerate Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -14 M | -19.4 M | -63.7 M | -72.8 M | -80.4 M | -64.2 M | -66.5 M | -45.5 M | -31 M | -15.3 M | -5.35 M | -409 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -409 K | -80.4 M | -39.9 M |
Quarterly Operating Income Accelerate Diagnostics
| 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -8.62 M | -8.61 M | - | -14.6 M | -12.6 M | -16.1 M | - | -15 M | -18 M | -15.9 M | -19.4 M | -14.5 M | -17.6 M | -20 M | -15.1 M | -15.2 M | -15.7 M | -17.7 M | -18.3 M | -17.7 M | -18.1 M | -18.8 M | -19.8 M | -19.4 M | -20.4 M | -20.8 M | -16.1 M | -17.3 M | -16.4 M | -14.3 M | -16 M | -17.4 M | -17.9 M | -15.2 M | - | -11.2 M | -12.3 M | -8.91 M | - | -8.83 M | -8.16 M | -5.75 M | - | -3.8 M | -3.78 M | -2.55 M | -344 K | -1.84 M | -1.15 M | -1.68 M | -47.6 K | -430 K | 2.34 K | -430 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.34 K | -20.8 M | -12.2 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 98.33 | 0.9 % | $ 8.11 B |  Irlanda |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 13.71 | -0.22 % | $ 99.4 M |  Israel |
 |
Charles River Laboratories International
CRL
|
25.2 M | $ 155.46 | 1.83 % | $ 7.71 B | USA |
 |
Bioventus
BVS
|
54 M | $ 8.62 | 0.23 % | $ 574 M | USA |
 |
DexCom
DXCM
|
912 M | $ 64.24 | -1.56 % | $ 25.1 B | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 25.56 | 0.95 % | $ 710 M | USA |
 |
CareDx, Inc
CDNA
|
-30.8 M | $ 17.01 | 3.4 % | $ 906 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-206 M | $ 103.57 | 0.29 % | $ 19.5 B | USA |
 |
Guardant Health
GH
|
-437 M | $ 85.49 | 1.75 % | $ 10.7 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M |  China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 14.77 | 0.61 % | $ 447 M | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 17.88 | -6.63 % | $ 2.32 B | USA |
 |
Anixa Biosciences
ANIX
|
-11.7 M | $ 2.83 | -1.05 % | $ 91.8 K | USA |
 |
Danaher Corporation
DHR
|
4.69 B | $ 187.32 | 0.57 % | $ 134 B | USA |
 |
IQVIA Holdings
IQV
|
2.18 B | $ 164.72 | 1.1 % | $ 28.3 B | USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Illumina
ILMN
|
-833 M | $ 118.94 | 2.92 % | $ 18.9 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.56 B | $ 199.7 | -0.46 % | $ 22.2 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Agilent Technologies
A
|
1.35 B | $ 111.51 | -0.06 % | $ 33.9 B | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.11 | -0.89 % | $ 1.41 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 9.0 | -0.99 % | $ 255 M | Israel |
 |
Neogen Corporation
NEOG
|
-1.06 B | $ 9.09 | -2.78 % | $ 1.97 B | USA |
 |
National Research Corporation
NRC
|
22.6 M | $ 16.52 | 0.12 % | $ 370 M | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Pacific Biosciences of California
PACB
|
-554 M | $ 1.33 | 4.72 % | $ 399 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 450.41 | 1.48 % | $ 13 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 114.22 | 3.11 % | $ 4.51 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 6.72 | 1.97 % | $ 398 M | USA |
 |
NeoGenomics
NEO
|
-116 M | $ 7.88 | -1.25 % | $ 1.01 B | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Natera
NTRA
|
-541 M | $ 187.85 | -1.29 % | $ 18.5 B | USA |
 |
Sotera Health Company
SHC
|
248 M | $ 13.42 | 0.71 % | $ 3.81 B | USA |
 |
Invitae Corporation
NVTA
|
-94.9 M | - | - | $ 21.2 M | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.19 | 2.59 % | $ 826 M | USA |